New and emerging targeted therapies for cystic fibrosis
- 30 March 2016
- Vol. 352, i859
- https://doi.org/10.1136/bmj.i859
Abstract
Cystic fibrosis (CF) is a monogenic autosomal recessive disorder that affects about 70 000 people worldwide. The clinical manifestations of the disease are caused by defects in the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The discovery of the CFTR gene in 1989 has led to a sophisticated understanding of how thousands of mutations in the CFTR gene affect the structure and function of the CFTR protein. Much progress has been made over the past decade with the development of orally bioavailable small molecule drugs that target defective CFTR proteins caused by specific mutations. Furthermore, there is considerable optimism about the prospect of gene replacement or editing therapies to correct all mutations in cystic fibrosis. The recent approvals of ivacaftor and lumacaftor represent the genesis of a new era of precision medicine in the treatment of this condition. These drugs are having a positive impact on the lives of people with cystic fibrosis and are potentially disease modifying. This review provides an update on advances in our understanding of the structure and function of the CFTR, with a focus on state of the art targeted drugs that are in development.This publication has 100 references indexed in Scilit:
- Correction of Both NBD1 Energetics and Domain Interface Is Required to Restore ΔF508 CFTR Folding and FunctionCell, 2012
- Requirements for Efficient Correction of ΔF508 CFTR Revealed by Analyses of Evolved SequencesCell, 2012
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationThe New England Journal of Medicine, 2011
- Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54Journal of Molecular Medicine, 2011
- Individual (N-of-1) trials can be combined to give population comparative treatment effect estimates: methodologic considerationsJournal of Clinical Epidemiology, 2010
- Integrated biophysical studies implicate partial unfolding of NBD1 of CFTR in the molecular pathogenesis of F508del cystic fibrosisProtein Science, 2010
- NMR evidence for differential phosphorylation-dependent interactions in WT and ΔF508 CFTRThe EMBO Journal, 2009
- Development of Novel Aminoglycoside (NB54) with Reduced Toxicity and Enhanced Suppression of Disease-Causing Premature Stop MutationsJournal of Medicinal Chemistry, 2009
- Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practiceJournal of Cystic Fibrosis, 2008
- PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR -G542X nonsense allele in a CF mouse modelProceedings of the National Academy of Sciences of the United States of America, 2008